PedAM
Pediatric Disease Annotations & Medicines
| Disease | diffuse large b-cell lymphoma |
| Phenotype | C0019163|hepatitis b |
| Sentences | 5 |
| PubMedID- 20837949 | Prospective analysis of hepatitis b virus reactivation in patients with diffuse large b-cell lymphoma after rituximab combination chemotherapy. |
| PubMedID- 26058465 | This study aimed to assess hbv reactivation and hepatitis occurrence in diffuse large b-cell lymphoma (dlbcl) patients with resolved hepatitis b receiving rituximab-containing chemotherapy compared with hbsag-negative/hbcab-negative patients to identify risk factors for hbv reactivation and hepatitis occurrence and to analyze whether hbv reactivation and hepatitis affect the survival of dlbcl patients with resolved hepatitis b. |
| PubMedID- 25848698 | We performed a retrospective study to analyse the characteristics and clinical outcomes of diffuse large b-cell lymphoma (dlbcl) patients with hepatitis b virus (hbv) infection and compare with those without hbv infection. |
| PubMedID- 22029053 | "prospective analysis of hepatitis b virus reactivation in patients with diffuse large b-cell lymphoma after rituximab combination chemotherapy". |
| PubMedID- 25514302 | Conclusions and relevance: among patients seropositive for the hepatitis b surface antigen with diffuse large b-cell lymphoma undergoing r-chop chemotherapy, the addition of entecavir compared with lamivudine resulted in a lower incidence of hbv-related hepatitis and hbv reactivation. |
Page: 1